IDEAYA Biosciences, Inc. (IDYA)
IDEAYA Biosciences, Inc. (IDYA) from its SEC filings: 2025 revenue $218.7 million (+3024% vs the year before), net margin -52%, free cash flow -$73.5 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $218.7 million |
| Revenue growth | +3024% |
| Net income | -$113.7 million |
| Net margin | -52.0% |
| Free cash flow | -$73.5 million |
| Diluted EPS | $-1.28 |
| Cash | $272.6 million |
| Share count, 1 year | +10% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.